Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Receives Overweight Rating from Cantor Fitzgerald

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 169.23% from the company’s previous close.

ATNM has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday. Maxim Group raised their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Finally, StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.72.

Actinium Pharmaceuticals Trading Up 5.7 %

Shares of NYSEAMERICAN ATNM traded up $0.42 during trading on Tuesday, reaching $7.80. The stock had a trading volume of 95,162 shares, compared to its average volume of 319,378. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86. The company has a market capitalization of $229.32 million, a price-to-earnings ratio of -4.28 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million during the quarter. As a group, equities analysts predict that Actinium Pharmaceuticals will post -1.87 earnings per share for the current year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brandywine Global Investment Management LLC bought a new position in Actinium Pharmaceuticals in the 3rd quarter worth approximately $1,033,000. Sanders Morris Harris LLC bought a new position in shares of Actinium Pharmaceuticals in the 1st quarter valued at about $78,000. Finally, Creative Financial Designs Inc. ADV raised its stake in shares of Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after buying an additional 3,175 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.